Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
1.
Medicine (Baltimore) ; 102(11): e33176, 2023 Mar 17.
Artículo en Inglés | MEDLINE | ID: mdl-36930120

RESUMEN

BACKGROUND: Coronary heart disease combined with depression is 1 of the 2 major diseases affecting physical and mental health. It has become a hot spot at the intersection of psychiatry and internal medicine. Most doctors call double heart medicine, which has a high incidence rate and a low diagnostic rate. Clinical research shows that Shugan Jieyu Decoction (SJD) has a better curative effect, increased safety, and fewer adverse reactions, but it lacks systematic evaluation. This study aims to integrate clinical data through network meta-analysis and provide more evidence-based medical evidence for clinical medication. METHODS: We searched 8 electronic databases: China knowledge network database, Wanfang, VIP, SinoMed, PubMed, Embase, WebofScience, Cochrane Library, and selected 22 randomized controlled trials from January 2012 to January 2022. The common primary endpoint was the relief of angina pectoris and the improvement of depression. Two researchers used Endnote9.1 software to conduct literature screening and information extraction according to the developed nano-passage standard, used Cochrane collaborative tool to evaluate the bias risk in the experiment, and then used RevMan5.3 software to assess the literature and data analysis synthesis. RESULTS: In 1908 patients with coronary heart disease and depression, the total effective rate of SJD in the treatment of angina pectoris was 3.49 (95% confidence interval, 1.93-6.29), as well as the network meta-analysis of improving depressive symptoms, anxiety, depression scores (SAS, SDS) and quality of life scores (HAMD), and reducing the indicators related to CPR and homocysteine. CONCLUSION: The analysis of this study shows that SJD can reduce the frequency of angina pectoris in patients with coronary heart disease and depression, alleviate anxiety and depression, provide a reference basis for clinical treatment, and select more effective intervention therapy.


Asunto(s)
Enfermedad Coronaria , Medicamentos Herbarios Chinos , Humanos , Angina de Pecho/complicaciones , Angina de Pecho/tratamiento farmacológico , Enfermedad Coronaria/complicaciones , Enfermedad Coronaria/tratamiento farmacológico , Depresión/complicaciones , Depresión/tratamiento farmacológico , Calidad de Vida , Metaanálisis en Red
2.
Hepatol Int ; 11(3): 221-241, 2017 May.
Artículo en Inglés | MEDLINE | ID: mdl-28405790

RESUMEN

Drug-induced liver injury (DILI) is an important clinical problem, which has received more attention in recent decades. It can be induced by small chemical molecules, biological agents, traditional Chinese medicines (TCM), natural medicines (NM), health products (HP), and dietary supplements (DS). Idiosyncratic DILI is far more common than intrinsic DILI clinically and can be classified into hepatocellular injury, cholestatic injury, hepatocellular-cholestatic mixed injury, and vascular injury based on the types of injured target cells. The CSH guidelines summarized the epidemiology, pathogenesis, pathology, and clinical manifestation and gives 16 evidence-based recommendations on diagnosis, differential diagnosis, treatment, and prevention of DILI.


Asunto(s)
Enfermedad Hepática Inducida por Sustancias y Drogas/epidemiología , Colestasis/inducido químicamente , Suplementos Dietéticos/efectos adversos , Hepatopatías/epidemiología , Antibacterianos/efectos adversos , Antibacterianos/toxicidad , Antiinfecciosos/efectos adversos , Antiinfecciosos/toxicidad , Enfermedad Hepática Inducida por Sustancias y Drogas/patología , Enfermedad Hepática Inducida por Sustancias y Drogas/fisiopatología , Enfermedad Hepática Inducida por Sustancias y Drogas/prevención & control , China/epidemiología , Colestasis/complicaciones , Colestasis/patología , Diagnóstico Diferencial , Suplementos Dietéticos/toxicidad , Medicamentos Herbarios Chinos/efectos adversos , Femenino , Guías como Asunto , Humanos , Incidencia , Hepatopatías/patología , Hepatopatías/fisiopatología , Hepatopatías/terapia , Masculino , Pronóstico , Factores de Riesgo , Índice de Severidad de la Enfermedad
3.
Zhonghua Yu Fang Yi Xue Za Zhi ; 45(2): 146-9, 2011 Feb.
Artículo en Chino | MEDLINE | ID: mdl-21426795

RESUMEN

OBJECTIVE: To explore the relation between the level of metallic elements in urine and childhood acute leukemia. METHODS: A total of 71 patients under 15 years old who were newly diagnosed with acute leukemia between September 2007 and August 2008 without Downs' syndrome or other tumors, and 113 gender- and age-matched controls without tumors or congenital diseases were enrolled for the case-control study. The general data and potential risk factors were obtained by questionnaires. Inductively coupled plasma mass spectrometry (ICP-MS) was used to determine the metal concentrations in urine, which was collected randomly before chemotherapy. Logistic regression model was performed for univariate and multivariate analysis. RESULTS: The questionnaire showed that there was significant difference in the proportion of children whose mothers had taken iron supplements during or 3 months before pregnancy between case group and control group, which was 28.2% (20/71) and 14.2% (16/113) respectively (Wald χ(2) = 5.438, P = 0.02). Univariate logistic regression analysis showed that levels of vanadium, manganese, iron, cobalt, copper, arsenic, and barium in urine from case group were all higher than those of control group with significant difference. The median values for vanadium in urine from case and control groups were 5.39 and 3.04 ng/mg creatinine (Wald χ(2) = 9.03, P < 0.05); the median values for manganese were respectively 4.46 and 2.44 ng/mg creatinine (Wald χ(2) = 10.57, P < 0.05); the median values for iron were separately 58.69 and 14.09 ng/mg creatinine (Wald χ(2) = 13.41, P < 0.05); the median values for cobalt were respectively 0.98 and 0.77 ng/mg creatinine (Wald χ(2) = 4.46, P < 0.05); the median values for copper were 61.17 and 10.90 ng/mg creatinine (Wald χ(2) = 8.15, P < 0.05); the median values for arsenic were respectively 55.93 and 36.11 ng/mg creatinine (Wald χ(2) = 4.57, P < 0.05); and the median values for barium were 8.55 and 2.87 ng/mg creatinine (Wald χ(2) = 4.82, P < 0.05). Multivariate logistic regression analysis showed that the level of iron in urine had a significantly positive relation with the incidence of childhood acute leukemia (OR = 1.009, 95%CI = 1.002 - 1.016). CONCLUSION: The level of iron in urine might be related to the occurrence of childhood acute leukemia, but its specific role needs further investigation.


Asunto(s)
Hierro/orina , Leucemia/etiología , Metales/orina , Enfermedad Aguda , Adolescente , Estudios de Casos y Controles , Niño , Preescolar , Femenino , Humanos , Lactante , Masculino
4.
Planta Med ; 76(3): 245-50, 2010 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-19774504

RESUMEN

Shenmai injection (SMI), a mixture of Radix Ginseng and Radix Ophiopogonis, is one of the most popular herbal medicinal products and is widely used for the treatment of coronary atherosclerotic cardiopathy and viral myocarditis. The purpose of this study was to investigate the effect of SMI, in vivo and in vitro, on the metabolic activities of hepatic cytochrome CYP450 3A1/2, 2C6, 2E1, and 1A2 in rats. After a single or multiple pretreatment with SMI, the rats were administrated intravenously a cocktail containing midazolam (1 mg/kg), diclofenac (0.5 mg/kg), theophylline (1 mg/kg), and chlorzoxazone (0.5 mg/kg) as probe substrates of rat CYP450 3A1/2, 2C6, 1A2, and 2E1, respectively. Single and multiple SMI pretreatment to rats resulted in a rise of 33.8 % (p < 0.01) and 25.6 % (p < 0.01) in AUC for midazolam, and an increase in AUC for diclofenac by 14.7 % (p < 0.05) and 31.2 % (p < 0.01), respectively. However, the pharmacokinetics of chlorzoxazone and theophylline in rats was not altered markedly. In rat liver microsomes, linear mixed-type inhibition of SMI against the enzyme activities of CYP3A1/2, CYP2C6, and CYP1A2 was shown with IC(50) values of 3.3 %, 2.0 %, and 3.1 % and K(i) values of 3.8 %, 1.5 %. and 1.9 %, respectively. These in vivo and in vitro results demonstrated that SMI had the potential to inhibit the activities of hepatic CYP3A1/2 and CYP2C6, but might not significantly affect CYP1A2 and CYP2E1-mediated metabolism in rats.


Asunto(s)
Sistema Enzimático del Citocromo P-450/metabolismo , Medicamentos Herbarios Chinos/farmacología , Interacciones de Hierba-Droga , Inactivación Metabólica , Hígado/efectos de los fármacos , Ophiopogon , Panax , Animales , Área Bajo la Curva , Clorzoxazona/farmacocinética , Sistema Enzimático del Citocromo P-450/efectos de los fármacos , Diclofenaco/farmacocinética , Combinación de Medicamentos , Concentración 50 Inhibidora , Inyecciones , Hígado/metabolismo , Masculino , Midazolam/farmacocinética , Raíces de Plantas , Ratas , Ratas Sprague-Dawley , Teofilina/farmacocinética
5.
Chem Biol Interact ; 180(3): 440-8, 2009 Aug 14.
Artículo en Inglés | MEDLINE | ID: mdl-19557931

RESUMEN

Shenmai injection (SMI), one of the most popular herbal preparations, is widely used for the treatment of coronary atherosclerotic cardiopathy and viral myocarditis. The purpose of this study was to investigate the effect of Shenmai injection (SMI) on the CYP3A-mediated metabolism of midazolam (MDZ). The present study demonstrated that SMI could significantly inhibit MDZ 4-hydroxylation but activate its 1'-hydroxylation in human liver microsomes (HLMs), rat liver microsomes (RLM) and recombinant human CYP3A4 and CYP3A5. The opposing effect of SMI was characterized by the kinetic change of increasing Vmax/Km for MDZ 1'-hydroxylation and decreasing Vmax/Km for MDZ 4-hydroxylation in HLM and RLM. The presence of SMI enhanced the inhibition of ketoconazole on MDZ 4-hydroxylation but weakened or reversed its inhibition on MDZ 1'-hydroxylation in HLM. After single or multiple pretreatment with SMI, the ratios of AUC(4-OH MDZ)/AUC(MDZ) in rats were significantly decreased, while the ratios of AUC(1'-OH MDZ)/AUC(MDZ) were increased. Among the major components in SMI, total ginsenoside (TG), ophiopogon total saponins (OTS), ophiopogon total flavone (OTF), ginsenoside Rd, ophiopogonin D and ophiopogonone A exhibited significant inhibition on both 4-hydroxylation and 1'-hydroxylation of MDZ in HLM and RLM, while no activation on MDZ metabolism was observed in the presence of these major constituents alone or together. To further explore the responsible components, 3 mL of SMI was loaded on a solid phase extraction (SPE) C18 cartridge and then separated by different concentrations of methanol. The fractions eluted with 60% and 90% methanol both showed significant activation on MDZ 1'-hydroxylation in HLM, but the fraction eluted with 30% methanol had no such effect. The results indicated that the activation of SMI on MDZ 1'-hydroxylation might be mainly resulted from the lipid-soluble components in SMI.


Asunto(s)
Citocromo P-450 CYP3A/metabolismo , Medicamentos Herbarios Chinos/farmacología , Midazolam/metabolismo , Animales , Inhibidores del Citocromo P-450 CYP3A , Combinación de Medicamentos , Humanos , Hidroxilación , Cetoconazol/farmacología , Cinética , Microsomas Hepáticos/efectos de los fármacos , Microsomas Hepáticos/enzimología , Ratas , Proteínas Recombinantes/antagonistas & inhibidores , Proteínas Recombinantes/metabolismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA